Showing results (371-380 of 388) with videos related to

Sort By:
Pageof 39
British Journal of Clinical Pharmacology|August 26, 2024
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary diseaseMuhammad Waqas Sadiq, Hongtao Yu, Magnus Åstrand, et al.
Plos Medicine|May 25, 2006
Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria InitiativeVerena Ilona Carrara, Supakit Sirilak, Janjira Thonglairuam, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
In vivo selection and glymphatic delivery of AAV5 capsids engineered to target human glial progenitor cellsAlexander Cona, Evan Newbold, Deniz Kesmen, et al.
Nature Biotechnology|July 8, 2026
Efficient targeting of human glial progenitor cells in vivo with engineered AAV vectors and glymphatic deliveryAlexander Cona, Evan Newbold, Deniz Kesmen, et al.
Plos Medicine|August 7, 2007
Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis)W Joost Wiersinga, Catharina W Wieland, Mark C Dessing, et al.
Clinical Pharmacology and Therapeutics|December 20, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary DiseaseFred Reid, Dave Singh, Muna Albayaty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2013
Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomesJoseph N Jarvis, Tihana Bicanic, Angela Loyse, et al.
The Journal of Allergy and Clinical Immunology|April 22, 2026
AZD8630/AMG 104, an inhaled Anti-TSLP antibody fragment, for moderate-to-severe asthma: a phase 1 randomized controlled trialSarah R Doffman, Davinder P S Dosanjh, Muhammad Waqas Sadiq, et al.
Pageof 39